Literature DB >> 15142629

Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression.

James A Bonner1, Donald J Buchsbaum, Suzanne M Russo, John B Fiveash, Hoa Q Trummell, David T Curiel, Kevin P Raisch.   

Abstract

PURPOSE: Elevated epidermal growth factor receptor (EGFR) expression has correlated with a poor prognosis after standard treatment of several malignancies. However, it is not clear whether the absolute level of EGFR expression affects the radiosensitizing properties of anti-EGFR treatments. A better understanding of this question would be helpful for the design of protocols that deliver these treatments. To explore this question, cells (LS174T) that did not display inherent anti-EGFR treatment-induced radiosensitization were selected for studies that could potentially enhance EGFR expression.
MATERIALS AND METHODS: Human colon carcinoma cells (LS174T), which did not show radiosensitization by anti-EGFR treatments, were employed for these studies. (Also, these cells were not responsive to the antiproliferative effects of anti-EGFR treatment.) Using standard transfection techniques (eukaryotic expression vector) as well as an adenoviral construct to enhance EGFR expression, LS174T cells were transduced in a manner that resulted in enhanced expression of EGFR. Subsequently, standard proliferation studies were performed to test the radiosensitizing properties of anti-EGFR treatment (an anti-EGFR monoclonal antibody: IMC-C225).
RESULTS: Studies were undertaken to stably transfect LS174T cells with EGFR. The stable transfectants, LS174T.EGFR cells, were responsive to the antiproliferative effects of anti-EGFR treatment, in contrast to the parent LS174T cells. Similar results were demonstrated when the cells were infected with AdEGFR. Additionally, the LS174T.EGFR cells were responsive to the radiosensitizing properties of anti-EGFR treatment (IMC-C225), whereas the parent cells were not.
CONCLUSIONS: Although the level of EGFR expression is of prognostic significance in many tumor models, the response of cells to anti-EGFR treatment alone, or combinations of this treatment with radiation or chemotherapy, depends upon many factors that are not necessarily related to the inherent EGFR expression of the tumor cells. However, the studies reported herein, demonstrate that when LS174T cells were transduced to show increased EGFR expression, they became responsive to the radiosensitizing properties of anti-EGFR treatments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142629     DOI: 10.1016/j.ijrobp.2004.01.053

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

1.  Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.

Authors:  L Pereboeva; S Komarova; J Roth; S Ponnazhagan; D T Curiel
Journal:  Gene Ther       Date:  2007-01-25       Impact factor: 5.250

2.  Multiplexed Five-Color Molecular Imaging of Cancer Cells and Tumor Tissues with Carbon Nanotube Raman Tags in the Near-Infrared.

Authors:  Zhuang Liu; Scott Tabakman; Sarah Sherlock; Xiaolin Li; Zhuo Chen; Kaili Jiang; Shoushan Fan; Hongjie Dai
Journal:  Nano Res       Date:  2010-01-01       Impact factor: 8.897

3.  Effect of cetuximab treatment in squamous cell carcinomas.

Authors:  Marika Nestor
Journal:  Tumour Biol       Date:  2010-02-24

4.  The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1α.

Authors:  Haiquan Lu; Ke Liang; Yang Lu; Zhen Fan
Journal:  Cancer Lett       Date:  2012-02-17       Impact factor: 8.679

5.  Thrombospondin-1 opens the paracellular pathway in pulmonary microvascular endothelia through EGFR/ErbB2 activation.

Authors:  Pallavi Garg; Shiqi Yang; Anguo Liu; Manuel A Pallero; Donald J Buchsbaum; Deane F Mosher; Joanne E Murphy-Ullrich; Simeon E Goldblum
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-04-29       Impact factor: 5.464

6.  Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.

Authors:  J Pablo Arnoletti; Donald J Buchsbaum; Zhi-qiang Huang; Ashley E Hawkins; Muhamad B Khazaeli; Matthias H Kraus; Selwyn M Vickers
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

Review 7.  Current and Emerging Clinical Applications of Multispectral Optoacoustic Tomography (MSOT) in Oncology.

Authors:  Lacey R McNally; Megan Mezera; Desiree E Morgan; Peter J Frederick; Eddy S Yang; Isam-Eldin Eltoum; William E Grizzle
Journal:  Clin Cancer Res       Date:  2016-05-20       Impact factor: 12.531

8.  Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinoma.

Authors:  James A Bonner; Hoa Q Trummell; Christopher D Willey; Brian A Plants; Kevin P Raisch
Journal:  Radiother Oncol       Date:  2009-07-16       Impact factor: 6.280

Review 9.  Molecular targets for tumor radiosensitization.

Authors:  Philip J Tofilon; Kevin Camphausen
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

10.  Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies.

Authors:  A Diaz Miqueli; J Rolff; M Lemm; I Fichtner; R Perez; E Montero
Journal:  Br J Cancer       Date:  2009-03-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.